Tranquis Therapeutics

Edit info

Founded: 2016

Location: Redwood City, CA

Employee range: 11 - 50

Clinical stage: Clin1

Therapy area: ALS

Drug types: NEU, MUS, GEN, IMM

Lead product: TQS-168

Funding: $30M A Jul 2020

Investors: Remiges Ventures, SR One, Vivo Capital, Hillsborough Venture, Correlation Ventures

tranquis.com

linkedin.com

job board

Drug notes:

Also Clin0 CNS conditions, muscular dystrophy, undisclosed; TQS-621 Clin0 Parkinson's, RD Alzheimer's; undisclosed programs RD neurological & immunological conditions

About:

Tranquis Therapeutics is developing therapeutics to treat a broad range of neurodegenerative diseases. Many neurodegenerative diseases are linked with metabolic dysfunction and impaired autophagy. To restore and reset the energy metabolism of dysfunctional immune cells, Tranquis is creating a portfolio of small molecule drugs that target the master regulators of mitochondrial and lysosomal function. These drugs switch the immune cells to become less inflammatory and more phagocytic so that they can maintain neuronal homeostasis. Tranquis is initially developing their therapeutic candidates to cross the blood brain barrier so that they can be used for a range of immune-mediated and mitochondrial diseases, beginning with amyotrophic lateral sclerosis.

Jobs:

Main

Contact: recruit@workinbiotech.com